| 0.1053 -0.063 (-37.43%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.16 | 1-year : | 0.19 |
| Resists | First : | 0.13 | Second : | 0.16 |
| Pivot price | 0.08  |
|||
| Supports | First : | 0.08 | Second : | 0.05 |
| MAs | MA(5) : | 0.1 | MA(20) : | 0.08 |
| MA(100) : | 0.12 |
MA(250) : | 1.08 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 60.5 | D(3) : | 60.5 |
| RSI | RSI(14): 53.2 | |||
| 52-week | High : | 5.17 | Low : | 0.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NSTG ] has closed below upper band by 20.3%. Bollinger Bands are 72.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.14 - 0.14 | 0.14 - 0.14 |
| Low: | 0.1 - 0.1 | 0.1 - 0.1 |
| Close: | 0.1 - 0.11 | 0.11 - 0.11 |
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
Mon, 05 Feb 2024
Why Is NanoString Technologies (NSTG) Stock Down 59% Today? - InvestorPlace
Fri, 17 Nov 2023
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies - PR Newswire
Mon, 06 Nov 2023
NanoString: Q3 Earnings Snapshot - qz.com
Mon, 06 Nov 2023
NanoString Technologies Inc (NSTG) Reports Q3 2023 Earnings: Revenue Grows by 63% Year on Year - Yahoo Finance
Mon, 28 Aug 2023
NanoString Appoints Todd Garland as Chief Commercial Officer - Business Wire
Wed, 08 Feb 2023
NanoString Technologies Stock: Looks Primed For A Steep Correction - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3.941e+007 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 5,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4849e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -102.5 % |
| Operating Margin | -75.9 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.6247e+008 % |
| Gross Profit (p.s.) | 50.64 |
| Sales Per Share | 23.03 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.13 |
| Dividend | 0 |
| Forward Dividend | 6.04e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|